Tsailas Panagiotis G, Babis George C, Nikolopoulos Konstantinos, Soucacos Panayotis N, Korres Dimitrios S
1st Orthopaedic Department, University of Athens School of Medicine. University General Hospital Attikon, Athens, Greece.
J Surg Res. 2009 Jan;151(1):108-14. doi: 10.1016/j.jss.2007.12.804. Epub 2008 Feb 1.
The purpose of this study was to present the effectiveness of 2 cyclooxygenase-2 inhibitors, meloxicam and parecoxib, in the prevention of heterotopic ossification. Eighteen white mature male rabbits were divided into 3 groups of 6 animals. One was the control group; 1 group was administered meloxicam subcutaneously, and 1 group was administered parecoxib subcutaneously. For the induction of heterotopic new bone, the Michelsson model was used. The extent of heterotopic new bone development was assessed according to Scott's classification. The meloxicam and parecoxib groups developed significantly less heterotopic bone when compared to the control group. There was no significant difference between the meloxicam and parecoxib group. We concluded that meloxicam and parecoxib are capable of preventing the development of heterotopic new bone in rabbits. The clinical relevance of this study is that meloxicam and parecoxib may be helpful in reducing heterotopic ossification in humans.
